(CercleFinance.com) – Pfizer today presents the first positive results of a phase 3 study on etrasimod as a treatment for severe active ulcerative colitis (UC).
In the study, patients treated with etrasimod achieved statistically significant improvements over placebo, with clinical remission at week 12, the primary endpoint.
Statistically significant improvements were also achieved for key secondary endpoints.
“These positive results demonstrate that etrasimod, if approved, could potentially be a breakthrough treatment option for patients with ulcerative colitis who may not experience improvements with current treatments,” said Michael Corbo, Development Director within the ‘Inflammation and Immunology’ division at Pfizer Global Product Development.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
